C
ostimulation through accessory molecules is thought to play a crucial role in lymphocyte activation (1) . One critical receptor/ligand interaction is between CD28/CTLA4 (2, 3) on T cells and B7 and related molecules on professional APCs such as dendritic cells and activated B ceils (4) (5) (6) (7) . Soluble forms of CTLA4 inhibit the induction of proliferation in vitro of most CD4 + clones (8) and block MLR reactions (9) . Furthermore, injection of mouse CTLA4-humanyl (mCTLA4-H'y1) 1 has been shown to inhibit T-dependent antibody production in vivo (10) , and rejection of nonvascularized xenografts in mice (11) , although prolongation of allograft survival has been more modest (12) .
To enable long-term studies of the potential of mCTLA4-H'y1 to modulate immune function, we generated transgenic mice that expressed mCTLA4-H3,1 in their serum, at levels similar to or greater than those achieved in earlier studies (5, 7) . Whereas T-dependent antibody responses were profoundly inhibited in these animals, we found to our surprise that priming of CD4 + cells was not impaired. In fact, paradoxically, hyperimmunized transgenic animals had increased 1 Abbreviations used in this paper: CD40L, CD40 ligand; f, primary follicle; FDC, follicular dendritic cells; gc, germinal center; mCD40-H'y1, mouse CD40-humanyl; mCD40L-mCD8a, soluble CD40 ligand; mCTLA4-H3'1, mouse CTLA4-human3~l; NP, nitrophenol; NP-C'yG, (4-hydroxy-3-nitrophenyl)-acetyl chicken gamma globulin. numbers of antigen-specific CD4 + cells, shown to be functional by their capacity to mediate the adoptive transfer of an antibody response (13) .
To understand the mechanism of antibody suppression we have investigated the transgenic mice more fully. Total Ig and IgG isotype levels, together with T-dependent IgG antihapten responses, are grossly reduced. This is not attributable to a nonspecific effect of the transgene as control transgenic mice make normal antibody responses. T-independent responses are normal, which implies that mCTLA4-H3,1 exerts its effect by blocking T cell help to B cells, not by affecting B cells directly through B7 and other CTLA4 ligands. Germinal center formation is absent, and is correlated with impaired switch to IgG isotypes, reduced somatic mutation and selection, and reduced antibody production.
Measurement of Antibody Titer and A~nity by ELISA. Specific
anti-DNP and anti-NP antibody titers were determined by ELISA. Antibody affinities for the haptens NP and DNP were measured according to the method described by Herzenberg et al. (20) . DNP10BSA, DNP3sBSA, NP11BSA, and NP3sBSA were coated onto 96owell plastic plates (Dynatech Laboratories, Inc., Chantilly, VA) at 50 ~g/ml hapten-carrier conjugate in 0.1 M borate buffer (pH 8.4) overnight at 4~ Plates were washed in PBS (pH 7.4) with 0.2% Tween 20 (Sigma Chemical Co.), and then blocked with PBS containing 1% FCS for i h at room temperature. Serial dilutions of serum in PBS containing 1% FCS were then applied, and incubated for 4 h at room temperature. After washing, peroxidaselabeled specific goat antisera directed against individual mouse isotypes (Southern Biotechnology Associates, Birmingham, AL) were added at the dilutions recommended, and binding of specific antibodies was revealed with the peroxidase substrate, ABTS | (Boehringer, Mannheim, Mannheim, Germany), diluted in citrate buffer (pH 4.6) as recommended. Plates were read on an ELISA reader at 405 nm.
Measurement of Mouse Immunoglobulin Subclasses and Human
IgGl. The concentrations of mouse immunoglobulin isotypes and subclasses in the sera of transgenic and control mice were measured using radial immunodiffusion plates (RID; Serotec Ltd., Oxford, UK). Levels of human IgG1 were estimated with RID plates provided by the same manufacturer.
lmmunohistology. Sections of spleen, lymph node, and Peyer's patch were taken from control and immunized mice and mounted in Tissue-tek embedding compound (Miles Scientific Division, Naperville, IL). 5-/zm frozen serial sections were cut and air dried, fixed in acetone at room temperature for 15 min, and stored in air tight containers at -20~ until use.
The expression of the transgene was detected using a biotinylated anti-human IgG antibody (Jackson Immunoresearch Laboratories, Inc., West Grove, PA). Geminal center B cells were identified by staining with biotinylated peanut (Arachis hypogaea) hemagglutinin (PNA) (Sigma Chemical Co.). Follicular dendritic cells (FDC) were identified in the sections using the rat anti-mouse FDC mAb, FDC-M1, generated in our laboratory. This was visualized using a mouse F(ab')~ anti-rat IgG (H and L chain-specific) conjugated to peroxidase (Jackson Immunoresearch Laboratories, Inc.). For labeling of NP-specific plasma cells, and to detect complexes of NP protein and antibody trapped on FDC's in follicles, sections were incubated with 1 #g/ml of NP-biotin-human-y-globulin (NP-bH3,G) in PBS containing 10 mg/ml of normal human-y-globulin to block nonspecific binding. After a 1 h incubation, the sections were washed three times in PBS, and endogenous peroxidase was blocked with PBS containing 0.3% H202 and 0.1% sodium azide. After further washing to remove traces of azide, the cells were incubated for 45 rain with streptavidin peroxidase complexes (Vectastain Elite ABC; Vector Laboratories, Inc., Burlingame, CA). All peroxidase reactions were developed using di-amino benzidine (1 mg/ml) (Sigma Chemical Co.) containing 0.1% H202 in PBS (pH 7.6). Specificity was checked on sections from nonimmunized controls, which did not bind NP-bH3,G. Immune complex trapping was assessed using aggregated rat antibody which binds by its Fc portion to receptors on FDC. As for the FDC-M1 mAb, the rat antibodies were visualized using the mouse anti-rat IgG reagent conjugated to peroxidase.
Cell Fusions. mCTLA4-Hyl transgenic mice and normal CS7BL/6 were primed with 100/zg NP coupled to NP-C3,G in alum. 6 wk later they were boosted with 100/xg NP-CyG i.p., and 3 wk after that received a tertiary immunization with 100/~g i.p. NP-CyG. 4 d after tertiary immunization, spleen cells from individual mice were fused with the myeloma fusion partner, Sp2/0 (21), using polyethylene glycol 1500 (Boehringer Mannheim). Fused cells were resuspended in IMDM supplemented with 2-ME (5 x 10 -s M), 10% FCS, r-glutamine, penicillin, and streptomycin, and plated into six 96-well flat-bottomed plates to which 5 x 104/well peritoneal feeder cells had previously been added. 24 h later, hypoxanthine, aminopterin, and thymidine (HAT) were added. Supernatants from wells were screened for h-bearing anti-NP antibodies. Positive wells were subcloned in hypoxanthine and thymidine medium containing supernatant from an IL6-secreting hybridoma to improve cloning efficiency.
Preparation of RNA, cDNA, PCR Amplification, and Subcloning intopBluescript Vectors. RNA from cloned hybridomas that secreted anti-NP antibodies were prepared as described elsewhere (22) . First-strand cDNA was synthesized using a kit (Boehringer Mannheim), and this served as template for subsequent PCR reactions.
The primers used to amplify the variable regions of IgM and IgG hybridomas were as described in (23) Purified PCR fragments were directly subcloned into pBluescript vector (Stratagene, Inc., LaJolla, CA). Briefly, the pBluescript vector was digested with EcoRV restriction enzyme (Boehringer Mannheim), and the linearized vector tailed with ddTTP using terminal transferase (Boehringer Mannheim). The purified PCR products were ligated with the ddT-tailed vector preparation with ligase (Boehringer Mannheim) overnight at 16~ and then transformed into competent Escherichia coli.
The insertion of the PCR fragment was confirmed by preparation of plasmid DNA, digestion with enzymes, and agarose gel electrophoresis.
Sequencing Reactions. Inserts from positive pBluescript clones were sequenced on both strands using plasmid primers and sequenase
820
B Cell Function in Mice Transgenic for mCTLA4-H3. (16) . 200,000 lymphocytes/well in a 96-well plate from control littermates or mCTLA4-H3'I transgenic mice were cultured for 3 d in the presence of medium alone (10% FCS containing glutamine, penicillin, streptomycin, and 2-ME), LPS (50/xg/ml) (Sigma Chemical Co.), or mCD40L-mCD8c~ (16) in combination with 1% supernatants from murine IL-2-, IL-4-, and IL-5-secreting clones (24) . Stimulations were done in the absence and presence of mCTLA4-Hyl (25 /xg/mt) final concentration (8) . 1 #Ci of [3H]thymidine/well was added for the last 16 h of culture. All assays were done in triplicate. Variation between triplicate wells was <10%.
Results

Generation of Mice
Transgenic for mCTLA 4-H3,1 and mCD40-Hyl. Transgenic mice that expressed soluble mCTLA4-Hyl and mCD40-Hyl were created as described in Materials and Methods. We identified three independent founder mice expressing mCTLA4-Hyl. All lines had the same phenotype. The expression of the transgenes is controlled by the mouse immunoglobulin heavy chain core enhancer and kappa promoter (25) , and the protein is expressed and secreted principally in B cells and plasma cells, although there is detectable transcription in RNA from thymus (26) , suggesting some low level of transcription in T cells. The mouse B cell immune system is not mature at birth but by 6 wk of age stable levels of expression (between 10 and 30/xg/ml) of the transgenic chimeric protein are achieved in the serum.
The capacity of these soluble molecules to bind and interfere with the normal interaction between receptor and ligand is dependent on: (a) the molar concentration of the soluble transgenic protein and the affinity of interaction of the ligand-receptor pair; and (b) accessibility of the soluble competitor to the ligand.
The molar concentrations of free mCTLA4-H3,1 and mCD40-H3,1 are ~10-7 M in these transgenic mice. The affinity/avidity of mCTLA4-Hyl for B7/BB1 is in the nanomolar range (27) . We have tested the binding at 37~ of sera from transgenic mice, and have observed that binding to activated B cells expressing B7/BB1 is saturated. In our hands, mCD40-Hyl binds less well to CD40 ligand (CD40L), at least compared with a decameric form of CD40, hCD40-H# (28), which probably accounts for the failure of mCD40-H'y1 to block CD40L. In addition, mCD40L is only upregulated after cognate interactions, so mCD40-Hyl may have less opportunity to compete with the physiological ligand.
Both mCTLA4-H3'I and mCD40-Hyl transgenic mice are healthy; there is no obvious difference from normal mice in their survival and fertility. They are tolerant to the soluble transgene just as they are to their own immunoglobulin. Grossly by FACS | analysis (Becton Dickinson & Co., Mountain View, CA), the proportions of B, CD4 +, and CD8 + cells are normal in the spleen and lymph node, although spleen and lymph nodes are smaller in mCTLA4-Hyl transgenic animals (data not shown). The size difference seems to be attributable to the lack of germinal centers in these animals (see later).
Impaired T-dependent but Not T-independent Responses.
Groups of mCTLA4-Hq,1 ( Fig. 1 A) or mCD40-H3/1 ( Fig.  1 B ) transgenic mice and their nontransgenic littermates were immunized with the T-dependent antigen DNP-KLH, initially in alum, and boosted with soluble antigen at the times indicated by arrows. There was no significant difference between mice transgenic for mCD40-H3'I and control animals, indicating that the introduction of the transgenic construct did not nonspecifically impair immunoglobulin production. In contrast, mCTLA4-Hq/1 transgenic mice made a negligible primary antibody response, and secondary responses were at least an order of magnitude lower than in control animals. This was not because antibody responses are simply slower in mCTLA4-H3,1 transgenic mice, as normal antibody levels were not achieved at longer intervals after immunization nor even after tertiary immunization.
In contrast to T-dependent responses, mCTLA4-H3,1 transgenic mice make normal responses to the T-independent antigen, TNP-Ficoll (Fig. 2 A) . Cross-linking surface immunoglobulin, as T-independent antigens might be expected to do, upregulates B7/BB1 on B cells (4) . These data would suggest that binding of mCTLA4-H'y1 to B7/BB1 exerts its effect by blocking an interaction with T cells rather than by acting directly on B cells.
Total Isotypes and Antihapten Isotypes. mCD40-Hyl trans-
genic animals had normal isotype-specific antihapten antibody responses to both T-dependent and T-independent antigens (data not shown). Measurement of isotype specific antihapten antibodies in mCTLA4-Hyl transgenic mice showed that levels of anti-DNP IgM antibodies overlapped in control and transgenic groups, but the IgG isotypes, IgG1, IgG2b, and IgG3, were ,'ol0-fold lower in transgenic animals ( Fig. 2 B) . In contrast, levels of IgM and IgG3 anti-TNP antibodies, the principal isotypes elicited by TNP-Ficoll, were comparable ( Fig. 2 A) . The decrease in IgG-specific anti-DNP titers was reflected in the total levels of IgG isotypes in mCTLA4-Hyl transgenic animals, which were again about an order of magnitude lower than controls (Fig. 3 A) . Levels of total IgG isotypes were comparable to controls in mCD40-H3d transgenic animals (Fig. 3 B) .
Impaired T-dependent Antibody Responses Are Not Due to a Direct Effect of mCTLA4-H3/1 on B Cells.
One possible explanation for the impaired T-dependent responses in these animals was that mCTLA4-H3'I co-cross-linked B7 on activated B cells with Fc receptors and specifically downregulated T-dependent antibody responses. To test this we took B cells from transgenic and control mice and stimulated them with either LPS (T-independent stimulus) or a soluble form of CD40L that we have previously generated (16) in the presence or absence of mCTLA4-H3'I (Table 1) . CD40L induces the expression of B7-1ike molecules on B cells as has been reported by others (6, 29) . Neither transgenic or control B cells were inhibited by the presence of mCTLA4-H3,1, suggesting that mCTLA4-H3,1 exerts its effect in vivo by blocking a specific interaction with T cells, and not by co-cross-linking B7 with Fc receptors.
Lack of Germinal Centers and Trapping of Antigen on
FDCs. Tissue sections from mCTLA4-H3'I and mCD40-H3,1 transgenic mice were incubated with antibodies directed against human 3'1. Lymph node sections from these mice are shown in Fig. 4 , A andB. In tissue from the mCTLA4-H3'I mice (Fig. 4 A) arrows) and FDC in the primary follicles (long arrows). Tissue from mCD40-H3"I transgenic mice (Fig. 4 B ) also showed plasma cell labeling (not seen in this micrograph) but none associated with accessory cells in the germinal center (gc) or paracortex. The monoclonal antibody FDC-M1 revealed that the FDC network was less extensive in mCTLA4-H3'I transgenic animals (Fig. 4 C) in comparison with nontransgenic mice (Fig. 4 D) . Tissue from control mice (Fig. 5 B) localized the NPcontaining immune complexes on FDC, formed germinal centers, and developed NP-specific plasma cells. In contrast to the spleen and lymph node, gut-associated lymphoid tissue from the mCTLA4-H3"I transgenic mice had normal germinal centers and levels of serum IgA were elevated.
A second marked anomaly in the mCTLA4-H3"I transgenics is their failure to localize immune complexes (Fig. 5  C) . This may be due to the low levels of IgG isotypes in their serum, as IgG complexes have been shown to localize much better than those of IgM (30) . However, passive immunization of mCTLA4-H3'I transgenic mice with high titer anti-DNP IgG antibody followed by immunization with 823 Lane et al. 
Lack of Selection and Reduced Somatic Mutation in mCTLA 4-H3"I Transgenic Mice.
In view of the absence of germinal centers, we tested for somatic mutation in the mCTLA4-H3'1 transgenic mice. In C57BL/6 mice the primary T-dependent response to NP is dominated by antibodies expressing a particular V. gene, 186.2, in association with hl light chains, and this subset of antibodies is also evident in secondary and tertiary immune responses to NP (31) .
We therefore hyperimmunized mCTLA4-H3,1 transgenic and control mice with NP-C3'G to maximize the chance of inducing somatic mutation. 4 d after the tertiary boosting, fusions were made in the standard manner. Positive hybridomas were identified by binding to NP and by their expression of X light chains. There were several pronounced differences between control and mCTLA4-H3,1 transgenic mice. First, the frequency of hybridomas was much higher in normal mice. We characterized 11 h-bearing anti-NP hybridomas from a normal mouse. 10 of these mAbs were 3'1 isotype and one expressed 3'2a. From 2 mCTLA4-H3"I transgenic mice, we found 10 hybridomas. Six hybridomas expressed IgM heavy chain isotype, three IgG3, and only one IgG1. We sequenced six of these clones and compared them with three sequences from the normal mice. The sequences of the V. regions of these hybridomas, are shown in Fig. 6 .
The three hybridomas shown from normal mice (C039, C041, and C043) all express V.186.2 heavy chains, together with the DFL16.1 D segment and JH2. All three hybridomas have extensive somatic mutations in their V regions (Fig. 6 A) . In particular all have a mutation at amino acid position 33, encoding a change from tryptophan to teucine. This mutation has been shown to increase the affinity for NP 10-fold (31). They have different NH2-terminal diversity Aq~G CAC TGG GTG AAG CAG AGG CCT GGA CGA GGC CTE GAG TGG A~'F GGA AC~ AT'P GAT CCT AAT AG~ GG~ C~GT AC'P AAC. T~ AA~ GAG AAG ~ AAG AC.C . ..................................................................................................  ........................................................................................... of their D segments indicating that they are not clonally related.
V186.2 sequences obtained from transgenic (T) and control (C) mice
S DJ sequences obtained from transgenic (T) and control (C) mice
Only one hybridoma, clone T099, from the mCTLA4-H3'1 mice expressed V.186.2 in association with DFL16.1 and JH2. The V. of this hybridoma was unmutated. The 3' junction of the DJ border shows no N sequence diversity, a characteristic feature of primary response hybridomas to NP (31) . The five other hybridomas expressed different V. genes. Clone T077 expressed V.23, a V. gene identified in the T-independent response to NP-Ficoll (32) . Clone T093 expressed V.124 (33), a V. gene closely related to V.186.2 but expressed by the BALB/c Ig ~ immunoglobulin haplotype in the response to NP. The mCTLA4-H3"I mice were generated in (DBA/2 x C57BL/6)F1 mice and although they have been backcrossed onto C57BL/6 and are homozygous at the MHC, they may still carry genes from the DBA/2 background. DBA/2 express the IgH a haplotype, of which V,124 is a member. Clone T142 expresses V~102.1, a VH gene closely related to V.186.2 (34) . Clone T210 expresses a V. gene expressed in the anti-DNP response in association with )x light chains (35) . Clone T210, like T077, and T093 express a proline (CCT) at position 7, a distinguishing feature of C57BL/6 NPb-related genes (36) .
All clones but one, from either transgenic or control mice, use DFL16.1 in association with either JH4 (three cases) or JH2 (five cases). The exception is hybridoma T093, which uses V.124, the IgH a V.186.2 equivalent gene, in association with DSP 2.2 and JH3.
While all control hybridomas are extensively somatically mutated, there are only four mutations in the transgenic hybridomas, clones T093 and T142. Because the V.186.2 gene family is so large, it is difficult to be sure that these are not closely related germline genes (32) . However, we also sequenced the ~, light chains (data not shown). The three normal hybridomas had five mutations in the Vr, whereas only one mutation was detected in the six transgenic hybridomas. Hybridoma T099 had no light chain mutations.
We made a comparative estimate of the affinities of the hybridomas by the method of Herzenberg et al. (20) . The binding of T099 represents the affinity of the germline V.186.2. As has been observed previously, the high affinity hybridomas, C039, C041, and C043, from the normal mouse bound at least as well to the low haptenated protein NPnBSA in ELISA compared to NP3sBSA, whereas T099 bound less well to NPllBSA than NP38BSA. The pattern for the other transgenic derived hybridomas was qualitatively the same as T099, suggesting they had lower affinities for NP than the control derived hybridomas (data not shown).
Discussion
This paper investigates in detail the defective antibody production in mCTLA4-H3d transgenic mice. In many respects these transgenic mice look phenotypicaUy like athymic nude mice. They have levels of IgM antibody within the normal range, but IgG isotypes are reduced, and they make normal TI-2 antibody responses. Unlike athymic mice, however, they make a T-dependent response to protein antigens, but with a greatly reduced IgG titer. To rule out the possibility that the defects in antibody production might be attributable to the expression of the transgene in B cells and plasma cells, we expressed mCD40-H~r as a transgene. The mCD40-H3d transgenic mice make antibody responses indistinguishable from those in normal mice. Another possibility is that the transgenic protein binds to CTLA4-1igand expressing cells which are then removed either by an interaction with complement or by antibody-dependent ceU-mediated cytotoxicity. We think this unlikely as the dendritic cell architecture in T cell areas, where B7 and related molecules are constitutively expressed, looks quite normal. In addition it seems unlikely that mCTLA4-H71 specifically downregulates B cell responses by co-cross-linking CTLA4-1igands and Fc receptors on B cells, as mCTLA4-H'y1 did not reduce the proliferation of B cells stimulated with soluble CD40L, a T-dependent stimulus that induces the expression of B7.
The functional defect in antibody production in mCTLA4-H3d transgenic mice is correlated with profoundly impaired gc formation, the cardinal feature of T-dependent antibody responses, gc's are locations where a few B cell precursors (37) proliferate at enormous rates (38) after immunization with T-dependent antigens. At least one of the important functions of gc's, therefore, is clonal amplification. Second, it is clear that germinal centers are sites where immunoglobulin class switching can occur. Follicular B cell blasts, the immediate precursors of the gc reaction, express IgM. Centrocytes, the progeny of germinal center centroblasts, almost invariably express IgG and IgA isotypes (39) . In addition, it has been proposed that somatic mutation is specifically switched on in B cells here (40) , and the accumulation of somatic mutations in germinal centers has been elegantly confirmed using microdissection and PCR (41) . Finally, it is considered likely that long-term antibody responses are maintained by the continuous stimulation of B cells with antigen retained on FDCs (42) . With respect to these aspects of gc function, mCTLA4-Hyl transgenic mice, with no gc's, behave as one might predict. They make poor responses to protein antigens, and have limited class switching. 
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that the transgenic mice are defective in the clonal expansion of B cells with high affinity for antigen. As in the T-independent response to NP (32), many V. genes closely related to V.186.2 but of low affinity are represented. B cells are activated initially in the T cell areas in T-dependent responses (39, 43, 44) where CTLA ligand is expressed on interdigitating cells (5, 8) . It is possible that some primary signal is blocked at this location in mCTLA4-H3,1 transgenic mice. However, staining of sections from mCTLA4-H3,1 transgenic mice showed localization of CTLA4 ligand on the FDC network, where it may have been trapped nonspecifically from degraded B cells as has been shown for class II molecules (45) . Alternatively, FDCs bearing CTLA4 ligand may form a local environment where trapped antigen, B cells, and the many T cells located in this part of the gc interact.
The earliest phase of the follicular reaction involves proliferation of slg-positive cells that have not switched (39) . This stage appears to be profoundly blocked in mCTLA4-H3,1 transgenic mice. The failure of these mice to class switch is reflected in the transgenic hybridomas. Virtually all hybridomas from normal mice express 3,1, whereas in transgenic animals # and 3'3 were the predominant isotypes, a profile more usually associated with T-independent responses (46) . It is emphasized that gut-associated lymphoid tissue is not affected in the transgenic mice. There is no obvious reason for this as the transgenic protein is expressed in gut-associated plasma cells.
Compared with normal mice, mCTLA4-H3,1 transgenic mice show reduced levels of somatic mutation. This is consistent with gc's being the principal site of somatic mutation, although a few mutations were observed in the transgenic hybridomas. What is clear from these studies is that the affinity of the hybridomas generated in mCTLA4-H3,1 transgenic mice is low. This is partly attributable to a lack of ability to selectively amplify B cells encoding high affinity germline genes. Somatic mutation is seen in V. genes in lower animals like Xenopus, which nevertheless have poor affinity maturation (47) . It has been speculated that the failure of Xenopus to make high affinity antibodies is caused by an inability to select mutants rather than a failure to generate them by somatic mutation, mCTLA4-H3,1 transgenic mice fail to localize immune complexes on FDCs and hence, in addition to their other defects, fail to provide an appropriate microenvironment in which selection of high affinity B cells can take place.
There are striking similarities between these mice and human patients with an antibody deficiency associated with hyper IgM that have a defect in the expression of CD40L on T cells (48) (49) (50) . Both have low IgG levels, impaired T-dependent antibody responses, and an absence of gc formation. Triggering of human T cells through CD3 is very poor at inducing the expression of CD40L (28) . However, it has recently been reported that B7/BB1 in conjunction with an anti-CD3 signal strongly upregulates CD40L (51) . The defects in mCTLA4-H3,1 transgenic mice could be explained by a failure of CTLA4 ligand expressing cells to upregulate CD40L on activated T cells, which consequently fail to supply help for B cells.
In summary, this report confirms and extends previous studies (10) showing that mCTLA4-H3'I can inhibit T-dependent antibody responses. It is not yet clear whether established antibody responses are similarly dependent on CTLA4 ligand. Enthusiasm for mCTLA4-H3,1 as a tool for suppressing T-dependent antibody responses must be tempered by the fact CD4 + T cells are primed normally. It is now clear that there are many ligands for CTLA4/CD28 (6, 7, 52) . Differential sensitivity of these costimulatory molecules to the blocking effects of mCTLA4-H3,1 would readily explain the apparent paradox that CD4 + cells are primed normally in the transgenic mice described here.
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